Solid Biosciences Inc.

NASDAQ:SLDB

Biotechnology

Healthcare
$6.23 +3.63%

+$0.27 today

Market cap
$695.33M
Beta
2.43
P/E (TTM)
-4.3
EPS (TTM)
-$1.75
52W Low $3.79High $8.87

Volume 1.13M

Average 1.39M

SLDB Net Income

Bottom-line profit after all expenses, interest, and taxes.

Solid Biosciences Inc.NASDAQ: SLDB

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$56.74M, compared with -$39.28M a year earlier. Trailing-twelve-month net income was -$191.78M.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 10 analysts of -$144.16M (+17.3%) for the fiscal year ending Dec 2026, a step up from the -39.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$56.74M-14.0% QoQ
Last fiscal yearDec 2025
-$174.33M-39.8% YoY
LTMMar 2026
-$191.78M-37.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.4%-68.3%-23.8 pp
1 year-39.8%+17.3%+57.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(174.33M) USD
Year-over-year change
-39.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How SLDB compares with its peers on the latest reported figures

  • SLDB's LTM Mar 2026 net income of -$191.78M is the 9th highest of the 10 companies compared; the peer median is -$98.64M.
  • Its year-over-year change of -37.3% is the 8th highest of 10, against a peer median of +8.8%.
SLDB Competitors Peer median
Net Income for SLDB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$1.01B +742.1%——
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$65.06M +126.2%—3.0%
PTCTPTC Therapeutics, Inc.LTM Jun 2026-$38.38M -106.1%—3.8%
PEPGPepGen Inc.LTM Mar 2026-$77.22M +24.4%——
NGNENeurogene Inc.LTM Mar 2026-$98.64M -22.0%——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026-$114.59M -108.1%——
MGTXMeiraGTx Holdings plcLTM Mar 2026-$120.53M +28.0%—151.1%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$160.9M +8.8%—182.3%
SLDBSolid Biosciences Inc.LTM Mar 2026-$191.78M -37.3%——
DYNDyne Therapeutics, Inc.LTM Jun 2026-$519.41M -25.8%——
Peer median (excluding SLDB) -$98.64M+8.8%—77.5%

Competitors are the stored peer set for SLDB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.62M8.09M000
Cost of Revenue002.58M2.46M1.64M
Gross Profit13.62M8.09M(2.58M)(2.46M)(1.64M)
Gross Margin100.0%100.0%———
Research & Development58.74M78.42M76.56M96.43M140.33M
Selling, General & Admin27.14M28.95M27.75M33.3M38.88M
Operating Expenses85.87M114.55M101.73M127.27M177.57M
Depreciation & Amortization2.96M2.41M2.58M2.46M1.64M
EBITDA(69.22M)(96.87M)(93.43M)(121.9M)(172.69M)
EBITDA Margin-508.3%-1196.8%———
Operating Income(72.25M)(106.45M)(104.32M)(129.73M)(179.21M)
Operating Margin-530.5%-1315.2%———
Interest Income64K2.62M7.14M9.47M9.9M
Interest Expense000340K0
Other Income / Expenses66K20.47M8.3M5.03M4.88M
Income Before Tax(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Pre-Tax Margin-530.0%-1062.3%———
Income Tax Expense00000
Net Income(72.19M)(85.98M)(96.02M)(124.7M)(174.33M)
Net Margin-530.0%-1062.3%———
EPS (Basic)(10.14)(10.10)(4.83)(3.06)(1.99)
EPS (Diluted)(10.14)(10.10)(4.83)(3.06)(1.99)
Weighted Avg Shares7.12M8.51M19.88M40.82M87.5M
Weighted Avg Shares (Diluted)7.12M8.51M19.88M40.82M87.5M

Solid Biosciences Inc.

NASDAQ:SLDB

Intrinsic Alpha fair value

Locked

Current Price

$6.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.